Human Papillomavirus and Cervical Health

Human papillomavirus (HPV) is the most common sexually transmitted infection, and persistent infection with high-risk genotypes is the necessary cause of nearly all cervical cancer as well as a substantial share of other anogenital and oropharyngeal cancers. Because most infections are acquired soon after sexual debut, HPV is central to adolescent sexual health, and vaccination of adolescents before exposure is a primary prevention strategy. This topic explains the virus, its link to cervical and other disease, and the logic of vaccination and screening.

Definition

Human papillomavirus infection is infection of skin and mucosal epithelium by papillomaviruses; in the genital tract, low-risk genotypes cause warts while persistent infection with high-risk (oncogenic) genotypes can cause cervical and other anogenital and oropharyngeal precancer and cancer.

Scope

The topic covers the spectrum of HPV genotypes (low-risk types causing genital warts, high-risk types causing cancer); the natural history from infection through persistence to precancer and cancer; the established causal link to cervical cancer; and the role of adolescent vaccination and cervical screening in prevention. It is descriptive reference material and not individualized clinical guidance.

Core questions

• Why is persistent high-risk HPV infection considered the necessary cause of cervical cancer?
• How does the natural history move from infection to precancer to invasive cancer?
• Why is HPV vaccination targeted at adolescents before sexual debut?
• How do vaccination and screening complement each other in prevention?

Key concepts

• High-risk (oncogenic) versus low-risk HPV genotypes
• Persistent infection
• Cervical intraepithelial neoplasia (precancer)
• Necessary cause of cervical cancer
• Anogenital and oropharyngeal cancers
• Prophylactic HPV vaccination
• Cervical screening (cytology and HPV testing)
• Genital warts

Mechanisms

Most genital HPV infections are transient and cleared by the immune system, but a minority persist. In persistent high-risk infection, viral oncoproteins (notably E6 and E7) disrupt cellular tumour-suppressor pathways, driving progressive epithelial dysplasia (cervical intraepithelial neoplasia) that can, over years, advance to invasive cancer. Because infection is typically acquired around the time of sexual debut, prophylactic vaccines that generate immunity before exposure prevent acquisition of the targeted genotypes; cervical screening provides a second layer of prevention by detecting precancerous lesions while they remain treatable.

Clinical relevance

The HPV–cervical cancer link underpins adolescent vaccination policy and adult cervical screening programmes, so understanding it is essential for appraising prevention evidence and guidelines. This entry describes mechanisms and population prevention at a reference level and is not a guide to vaccination, screening, or treatment decisions for any individual.

Epidemiology

HPV is the most common STI, with most sexually active people acquiring it at some point; high-risk genotypes account for nearly all cervical cancer worldwide, as reviewed by Crosbie and colleagues. Population studies, including the cohort analysis by Lei and colleagues, show that HPV vaccination is associated with a reduced risk of invasive cervical cancer, particularly when given at younger ages, and trial evidence such as Palefsky and colleagues demonstrates protection against anal HPV-related disease.

History

The recognition that specific high-risk HPV genotypes cause cervical cancer, established through virological and epidemiological work in the late twentieth century, reframed cervical cancer as a vaccine-preventable, infection-driven disease. Licensure of prophylactic HPV vaccines in the mid-2000s, followed by accumulating real-world cohort evidence of reduced cancer risk, has progressively shifted cervical cancer prevention toward adolescent vaccination alongside screening.

Debates

How should vaccination and screening be combined as cervical screening evolves?

As vaccinated cohorts age and primary HPV testing replaces cytology in many programmes, the optimal integration of vaccination with screening intervals and methods is an evolving policy question.

Seminal works

• crosbie-2013
• lei-2020
• palefsky-2011

Frequently asked questions

Does every HPV infection lead to cancer?

No. Most HPV infections are transient and clear on their own; only persistent infection with high-risk genotypes carries an appreciable risk of progressing to precancer and, rarely, invasive cancer.

Why is HPV vaccine recommended for adolescents rather than adults?

Because most HPV is acquired soon after sexual debut, prophylactic vaccination produces the greatest benefit when given before exposure, which is why it targets adolescents.